The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Hengrui Pharmaceutical; Innovent Biologics; MSD; TopAlliance BioSciences Inc
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Hengrui Pharmaceutical; Innovent Biologics; TopAlliance BioSciences Inc
Research Funding - Bayer; Eisai; Hengrui Pharmaceutical
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Delcath Systems; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; Eisai; Gilead Sciences; Ipsen; Lilly; Roche; Sanofi
Consulting or Advisory Role - Amgen; ArQule; Basilea; Baxter; Bayer; Celgene; Eisai; Exelixis; Hengrui Therapeutics; Incyte; Ipsen; Italfarmaco; Lilly; Merck Sharp & Dohme; Roche; Sanofi; Sirtex Medical
Research Funding - Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - ArQule; Ipsen
 
Hui-Chuan Sun
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Bristol-Myers Squibb; Celgene; CytomX Therapeutics (I); Debiopharm Group; Eisai; Exelixis; Flatiron Health; Flatiron Health; Genoscience Pharma; Gilead Sciences; Ipsen; Janssen (I); LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; Pfizer (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; Silenseed (I); Sillajen; SOBI (I); Targovax (I); twoXAR; Vicus Therapeutics; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); Novartis (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
Anthony B. El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
David James Pinato
Consulting or Advisory Role - Eisai; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb; MSD Oncology
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb
 
Monica Daigl
Employment - F. Hoffmann LaRoche
Stock and Other Ownership Interests - F. Hoffmann LaRoche
 
Javier Sanchez Alvarez
Employment - F. Hoffmann LaRoche
Stock and Other Ownership Interests - F. Hoffmann LaRoche
 
Panos Orfanos
Employment - F. Hoffmann LaRoche
 
Michael Leibfried
Employment - F. Hoffmann LaRoche
Stock and Other Ownership Interests - F. Hoffmann LaRoche
Travel, Accommodations, Expenses - F. Hoffmann LaRoche
 
Marie-Hélène Blanchet Zumofen
Employment - F. Hoffmann LaRoche
Consulting or Advisory Role - F. Hoffmann LaRoche
 
Vincent Gaillard
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma